Keppra and Sluggishness - a phase IV clinical study of FDA data

Summary:

Sluggishness is reported as a side effect among people who take Keppra (levetiracetam), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Dilantin, and have Brain neoplasm malignant.

The phase IV clinical study analyzes which people have Sluggishness when taking Keppra. It is created by eHealthMe based on reports of 70,297 people who have side effects when taking Keppra from the FDA, and is updated regularly.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.

What is Sluggishness?

Sluggishness (lacking alertness) is found to be associated with 783 drugs and 748 conditions by eHealthMe. Check the latest studies of Sluggishness.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

70,297 people reported to have side effects when taking Keppra.
Among them, 48 people (0.07%) have Sluggishness.

Among these 48 people:

How long have people been on Keppra when they have Sluggishness? *

What is the gender of people who have Sluggishness when taking Keppra? *

female: 65.12 %
male: 34.88 %

What is the age of people who have Sluggishness when taking Keppra? *

What are other drugs people take besides Keppra? *

What are other side effects people have besides Sluggishness? *

Fatigue (feeling of tiredness): 14 people, 29.17%
Weight Increased: 9 people, 18.75%
Headache (pain in head): 8 people, 16.67%
Memory Loss: 8 people, 16.67%
Dizziness: 7 people, 14.58%
Bradyphrenia (neurological term referring to the slowness of thought common to many disorders of the brain): 6 people, 12.50%
Depression: 6 people, 12.50%
Mood Swings (an extreme or rapid change in mood): 6 people, 12.50%
Panic Disorder: 5 people, 10.42%
Brain Neoplasm Malignant (brain cancer tumour): 5 people, 10.42%

What are the existing conditions these people have? *

Brain Neoplasm Malignant (brain cancer tumour): 5 people, 10.42%
Peripheral Coldness: 3 people, 6.25%
Insomnia (sleeplessness): 3 people, 6.25%
Skin Injury: 2 people, 4.17%
Muscle Spasms (muscle contraction): 2 people, 4.17%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 2 people, 4.17%
Grand Mal Convulsion (a type of generalized seizure that affects the entire brain): 1 person, 2.08%
Birth Control: 1 person, 2.08%
Blood Testosterone Decreased: 1 person, 2.08%
Bone Disorder: 1 person, 2.08%

* Approximation only. Some reports may have incomplete information.

Do you take Keppra and have Sluggishness?

- Check whether Sluggishness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keppra:

Keppra (73,504 reports)

Sluggishness treatments and more:

Sluggishness (11,737 reports)

Browse all side effects of Keppra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sluggishness:

Sluggishness (783 drugs)

Browse all the conditions that are associated with Sluggishness:

Sluggishness (748 conditions)

Related publications that referenced our studies

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on levetiracetam (the active ingredients of Keppra) and Keppra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.